CompletedNot Applicable

Urine-based Molecular Testing vs Cystoscopy for Surveillance of Nonmuscle Invasive Bladder Cancer (NMIBC)

United States107 participantsStarted 2023-11-16

Plain-language summary

The purpose of this study is to evaluate patient-reported preference for urine based molecular testing (CxBladder Monitor) compared to cystoscopy for patients on surveillance for Nonmuscle Invasive Bladder Cancer (NMIBC). Urine based molecular testing involves noninvasive testing of a urine sample for biomarkers associated with disease recurrence. Cystoscopy is an examination of the bladder and urethra using a thin tube like instrument that is inserted into the urethra.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Male or female with a history of histologically confirmed nonmuscle invasive bladder cancer (NMIBC) who have at least 6 months of disease-free survival from last recurrence. * Able to provide urine for testing and comply with study protocol. * Have an email address and be willing to complete surveys online. Exclusion Criteria: * History of non-urothelial bladder cancer (primary squamous, adenocarcinoma, and small cell carcinoma) * Patients with predominant (\>50%) variant histology * Patients with a history of upper tract and/or urethral cancer * Women who are pregnant

What they're measuring

Preference for CxBladder Monitor compared to cystoscopy

Timeframe: Up to 6 months

Trial details

NCT IDNCT06126796

SponsorMayo Clinic

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-08

View on ClinicalTrials.gov More Non-muscle Invasive Bladder Cancer trials